Research company RTI International reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for the new drug pretomanid for treating Extensively Drug-Resistant Tuberculosis (XDR-TB) and intolerant/non-responsive Multidrug-Resistant (MDR) TB under partnership with the National Institute of Allergy and Infectious Diseases (NIAID) and TB Alliance.
In conjunction with the FDA approval, TB Alliance has negotiated licence agreements enabling an affordable cost of pretomanid in low resource countries.
Pretomanid , also known as Pa-824, is only the third anti-TB drug approved by FDA in more than 40 years. The six-month, all-oral BPaL (bedaquiline and linezolid) regimen cured nine out of ten participants of the XDR-TB patients in the trials conducted in South Africa. RTI scientist Doris Rouse led institute work to develop the treatment with a success rate of 89%.
XDR-TB is resistant to four of the main drugs, including injectable agents, currently used to treat drug resistant TB around the world.
TB Alliance is now targeting adoption and availability of pretomanid as part of the BPaL regimen in countries with a high unmet need for XDR-TB treatments.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial